Status:
UNKNOWN
Bucillamine Study of Holding Remission After Infliximab Dose-off
Lead Sponsor:
Saitama Medical University
Collaborating Sponsors:
Keio University
Conditions:
Rheumatoid Arthritis
Eligibility:
All Genders
20+ years
Phase:
PHASE4
Brief Summary
Patients with rheumatoid arthritis who have been well controlled with methotrexate plus infliximab may remain in remission or low disease activity without infliximab. And the chance of sustained remis...
Eligibility Criteria
Inclusion
- RA according to American College of Radiology (ACR) classification criteria
- Age of 20 or greater
- DAS28-ESR \< 3.2 or DAS28-CRP \< 2.6 for more than 6 months
Exclusion
- Previously teated with bucillamine
- Pregnancy or lactation
Key Trial Info
Start Date :
January 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT00716248
Start Date
January 1 2007
Last Update
January 5 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Rheumatology/Clinical Immunology, Saitama Medical Center, Saitama Medical University
Kawagoe, Saitama, Japan, 350-8550